Literature DB >> 18725590

Natural history of SMA IIIb: muscle strength decreases in a predictable sequence and magnitude.

Feza Deymeer1, Piraye Serdaroglu, Yesim Parman, Mehves Poda.   

Abstract

OBJECTIVE: To assess the natural progression of muscle weakness in spinal muscular atrophy (SMA) IIIb.
METHODS: Ten patients with SMA IIIb were followed for at least 10 years. Age at disease onset varied between 9 and 18 years. Patients were initially seen 2 to 10 years after disease onset. They were evaluated at approximately 2, 5, 10, 15, and 20 years of disease duration depending on the timing of their initial visit after onset. Medical Research Council (MRC) scale was used with particular attention to proximal muscles.
RESULTS: The MRC grade declined with years in all of the muscles. The decline was usually not more than by one MRC grade for each 5-year period. There were 5-10 year periods when some muscles appeared to remain stationary. The succession of weakness was first triceps, then biceps and deltoid for upper extremity muscles and first thigh adductors, then iliopsoas, then quadriceps femoris, then hamstrings, thigh abductors, and gluteus maximus for lower extremity muscles. There was a remarkable uniformity between patients in the MRC grade for each muscle at each stage: in the first 5 years of the disease, triceps, iliopsoas, thigh adductors, and quadriceps femoris were the muscles which had noticeable weakness.
CONCLUSIONS: These findings show that strength in spinal muscular atrophy IIIb decreases over time, explaining the progressive functional loss. The sequence of weakness in the lower extremities suggests that the disease starts segmentally involving the upper lumbar segments of the medulla spinalis initially. The slowness of the deterioration may have implications for clinical trials.

Entities:  

Mesh:

Year:  2008        PMID: 18725590     DOI: 10.1212/01.wnl.0000324623.89105.c4

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

1.  Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study.

Authors:  Giorgia Querin; Timothée Lenglet; Rabab Debs; Tanya Stojkovic; Anthony Behin; François Salachas; Nadine Le Forestier; Maria Del Mar Amador; Gaëlle Bruneteau; Pascal Laforêt; Sophie Blancho; Véronique Marchand-Pauvert; Peter Bede; Jean-Yves Hogrel; Pierre-François Pradat
Journal:  J Neurol       Date:  2021-01-02       Impact factor: 4.849

2.  Resistance strength training exercise in children with spinal muscular atrophy.

Authors:  Aga Lewelt; Kristin J Krosschell; Gregory J Stoddard; Cindy Weng; Mei Xue; Robin L Marcus; Eduard Gappmaier; Louis Viollet; Barbara A Johnson; Andrea T White; Donata Viazzo-Trussell; Philippe Lopes; Robert H Lane; John C Carey; Kathryn J Swoboda
Journal:  Muscle Nerve       Date:  2015-10       Impact factor: 3.217

3.  Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year.

Authors:  Petra Kaufmann; Michael P McDermott; Basil T Darras; Richard Finkel; Peter Kang; Maryam Oskoui; Andrei Constantinescu; Douglas Michael Sproule; A Reghan Foley; Michele Yang; Rabi Tawil; Wendy Chung; Bill Martens; Jacqueline Montes; Jessica O'Hagen; Sally Dunaway; Jean M Flickinger; Janet Quigley; Susan Riley; Allan M Glanzman; Maryjane Benton; Patricia A Ryan; Carrie Irvine; Christine L Annis; Hailly Butler; Jayson Caracciolo; Megan Montgomery; Jonathan Marra; Benjamin Koo; Darryl C De Vivo
Journal:  Arch Neurol       Date:  2011-02-14

4.  Prospective cohort study of spinal muscular atrophy types 2 and 3.

Authors:  Petra Kaufmann; Michael P McDermott; Basil T Darras; Richard S Finkel; Douglas M Sproule; Peter B Kang; Maryam Oskoui; Andrei Constantinescu; Clifton L Gooch; A Reghan Foley; Michele L Yang; Rabi Tawil; Wendy K Chung; William B Martens; Jacqueline Montes; Vanessa Battista; Jessica O'Hagen; Sally Dunaway; Jean Flickinger; Janet Quigley; Susan Riley; Allan M Glanzman; Maryjane Benton; Patricia A Ryan; Mark Punyanitya; Megan J Montgomery; Jonathan Marra; Benjamin Koo; Darryl C De Vivo
Journal:  Neurology       Date:  2012-10-17       Impact factor: 9.910

Review 5.  Biomarkers in rare disorders: the experience with spinal muscular atrophy.

Authors:  Francesco D Tiziano; Giovanni Neri; Christina Brahe
Journal:  Int J Mol Sci       Date:  2010-12-24       Impact factor: 5.923

Review 6.  Physical exercise training for type 3 spinal muscular atrophy.

Authors:  Bart Bartels; Jacqueline Montes; W Ludo van der Pol; Janke F de Groot
Journal:  Cochrane Database Syst Rev       Date:  2019-03-01

7.  Expression of Muscle-Specific MiRNA 206 in the Progression of Disease in a Murine SMA Model.

Authors:  Valeria Valsecchi; Marina Boido; Elena De Amicis; Antonio Piras; Alessandro Vercelli
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

8.  A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy Controls.

Authors:  Renske I Wadman; Marloes Stam; Marc D Jansen; Yana van der Weegen; Camiel A Wijngaarde; Oliver Harschnitz; Peter Sodaar; Kees P J Braun; Dennis Dooijes; Henny H Lemmink; Leonard H van den Berg; W Ludo van der Pol
Journal:  PLoS One       Date:  2016-11-28       Impact factor: 3.240

9.  Comparison of independent screens on differentially vulnerable motor neurons reveals alpha-synuclein as a common modifier in motor neuron diseases.

Authors:  Rachel A Kline; Kevin A Kaifer; Erkan Y Osman; Francesco Carella; Ariana Tiberi; Jolill Ross; Giuseppa Pennetta; Christian L Lorson; Lyndsay M Murray
Journal:  PLoS Genet       Date:  2017-03-31       Impact factor: 5.917

10.  Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial).

Authors:  Marloes Stam; Renske I Wadman; Camiel A Wijngaarde; Bart Bartels; Fay-Lynn Asselman; Louise A M Otto; H Stephan Goedee; Laura E Habets; Janke F de Groot; Marja A G C Schoenmakers; Inge Cuppen; Leonard H van den Berg; W Ludo van der Pol
Journal:  BMJ Open       Date:  2018-07-30       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.